Merck & Co., Inc. (MRK) Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
Merck & Co., Inc. (MRK) Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
Merck & Co., Inc. (MRK) KEYTRUDA (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
Merck & Co., Inc. (MRK) KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
ADVERTISEMENT
Merck & Co., Inc. (MRK) Sec Form 10K
Merck & Co., Inc. (NYSE: MRK) Sec Form 10K
Merck & Co., Inc. (MRK) TD Cowen 46th Annual Health Care Conference
Merck & Co., Inc. (NYSE: MRK) FY 2026 Corporate Conference
Merck & Co., Inc. (MRK) Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
ADVERTISEMENT
Merck & Co., Inc. (MRK) Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
Merck & Co., Inc. (MRK) KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release